3H Biomedical AB

www.3hbiomedical.com

3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.

Read more

Reach decision makers at 3H Biomedical AB

Lusha Magic

Free credit every month!

3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.

Read more
icon

Country

icon

City (Headquarters)

Uppsala

icon

Employees

1-10

icon

Founded

2004

icon

Estimated Revenue

$1 to $1,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Owner

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at 3H Biomedical AB

Free credits every month!

My account

Sign up now to uncover all the contact details